Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint

21.07.2023 - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which ...

Related Keywords

United States ,Lang Schwarz ,Linkedin ,Twitter ,Exchange Commission ,Facebook ,Instagram ,Daxdilimab Phase ,Systemic Lupus ,Systemic Lupus Erythematosus Responder Index ,Looking Statements ,United States Securities ,Horizon Therapeutics Stock ,